Affimed Therapeutics
NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
Launch date
Employees
Market cap
$62.7m
Enterprise valuation
$40m (Public information from Sep 2024)
Share price
$4.02 AFMD
Company register number HRB 721206 (Mannheim)
Heidelberg Baden-Württemberg (HQ)
Authorizing premium user...